Women infected with HBV include three main groups of people. The first is the immune tolerance period, which is characterized by normal liver function indicators, positive HBVDNA, and imaging results suggesting no significant liver progression, and requires a comprehensive evaluation of liver compensatory function before preparing for pregnancy, with recommendations made jointly by obstetricians and gynecologists and hepatologists; the second is the chronic hepatitis B population, which has received antiviral therapy and requires a comprehensive liver function evaluation before preparing for pregnancy, just like the immune tolerance period population The second group of people with chronic hepatitis B, who are already on antiviral therapy, need to undergo a comprehensive liver function evaluation before preparing for pregnancy, just like the immune tolerance group, and need to change their anti-HBV medication to pregnancy class B medication, which will be recommended by obstetrics and gynecology and hepatologists; the third group of people with inactive HBsAg carriers, who are characterized by normal liver function indicators, HBVDNA below the lower limit of detection, and imaging results indicating no significant liver progression, also need to undergo a comprehensive liver function evaluation before preparing for pregnancy, just like the first two groups. A comprehensive liver function evaluation is performed and a recommendation is made jointly by the obstetrician-gynecologist and the hepatologist. After pregnancy, liver function indicators are monitored during early, mid and late pregnancy and if there are any abnormalities, treatment is carefully considered by the physician depending on the pregnancy. Anti-HBV drugs may also be considered in late pregnancy for women with immune-tolerant pregnancies, but they must be applied under the guidance of a physician. If liver inflammation develops during pregnancy, the pregnancy may continue under close observation, and significant liver inflammation will require pharmacological intervention. Injection of hepatitis B highly effective immunoglobulin in a dose greater than or equal to 100 IU within 24 hours (preferably 12 hours) after the birth of the child, along with 10ug of recombinant yeast hepatitis B vaccine at different sites, and a second and third dose of hepatitis B vaccine at 1 month and 6 months of age respectively, can significantly improve the effectiveness of blocking mother-to-child transmission of hepatitis B. Breastfeeding by the mother is acceptable after the implementation of mother-to-child blocking measures.